Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.

Authors:
Griffith SP; Wesselingh R; Seery N; Rushen T; Kyndt C and 9 more

Journal:
J Neurol

Publication Year: 2023

DOI:
10.1007/s00415-023-11967-w

PMCID:
PMC10770222

PMID:
37709946

Journal Information

Full Title: J Neurol

Abbreviation: J Neurol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflicts of interestProf Terence O’Brien has received support from the National Health and Medical Research Council, The National Institute of Neurological Disorders and Stroke and Monash University. He has been supported by research grants and consultancies to his institution from Eisai, UCB Pharma, Praxis Precision Medicines, BioGen and Supernus. Dr Mastura Monif has received research support from National Health and Medical Research Council, Medical Research Future Fund, Brain Foundation, Charles and Sylvia Viertel Foundation, and MS Research Australia. MM has also been supported by research grants from Merck and Ku Leuven University, served on advisory board for Merck, has received speaker honoraria from Merch and Biogen. Dr Katherine Buzzard has received speaker’s honoraria and/or conference support from Biogen, Alexion, Merck, Sanofi Genzyme, Teva, Novartis and Roche. KB has received research grants from CSL and has served on advisory boards for Merck and Biogen. Prof Helmut Butzkueven’s research is funded by an Australian National Health Medical Research Council Investigator Grant. His institution receives funding from Biogen, Roche, Merck, Alexion and Novartis for speaker engagements, study steering and advisory committee service. He is on the editorial board of Multiple Sclerosis and Related Disorders and the Steering committee of the Brain Health Initiative (Oxford Health Policy Forum). Associate Professor Charles Malpas has received conference travel support from Merck, Novartis, and Biogen. He has received research support from the National Health and Medical Research Council, Multiple Sclerosis Research Australia, The University of Melbourne, The Royal Melbourne Hospital Neuroscience Foundation, and Dementia Australia. Associate Professor Udaya Seneviratne has received travel and speaker honoraria from Eisai Australia and LivaNova Australia. The remaining authors report no conflicts of interest. Ethical approvalThis study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the central Human Research Ethics Committee at Alfred Health approved the study (HREC/17/Alfred/168). Conflicts of interest Prof Terence O’Brien has received support from the National Health and Medical Research Council, The National Institute of Neurological Disorders and Stroke and Monash University. He has been supported by research grants and consultancies to his institution from Eisai, UCB Pharma, Praxis Precision Medicines, BioGen and Supernus. Dr Mastura Monif has received research support from National Health and Medical Research Council, Medical Research Future Fund, Brain Foundation, Charles and Sylvia Viertel Foundation, and MS Research Australia. MM has also been supported by research grants from Merck and Ku Leuven University, served on advisory board for Merck, has received speaker honoraria from Merch and Biogen. Dr Katherine Buzzard has received speaker’s honoraria and/or conference support from Biogen, Alexion, Merck, Sanofi Genzyme, Teva, Novartis and Roche. KB has received research grants from CSL and has served on advisory boards for Merck and Biogen. Prof Helmut Butzkueven’s research is funded by an Australian National Health Medical Research Council Investigator Grant. His institution receives funding from Biogen, Roche, Merck, Alexion and Novartis for speaker engagements, study steering and advisory committee service. He is on the editorial board of Multiple Sclerosis and Related Disorders and the Steering committee of the Brain Health Initiative (Oxford Health Policy Forum). Associate Professor Charles Malpas has received conference travel support from Merck, Novartis, and Biogen. He has received research support from the National Health and Medical Research Council, Multiple Sclerosis Research Australia, The University of Melbourne, The Royal Melbourne Hospital Neuroscience Foundation, and Dementia Australia. Associate Professor Udaya Seneviratne has received travel and speaker honoraria from Eisai Australia and LivaNova Australia. The remaining authors report no conflicts of interest."

Evidence found in paper:

"Funding Open Access funding enabled and organized by CAUL and its Member Institutions. This work was supported by NHMRC Medical Research Future Fund (APP1201062)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025